# Wendelin Maners

> Wendelin Maners is the President and CEO of CSA Medical, the Lexington, Massachusetts medical-device company behind the RejuvenAir System, a liquid-nitrogen cryospray technology delivered by bronchoscope. A finance-trained dealmaker who spent years buying and licensing emerging technologies for Boston Scientific, Maners moved from the deal table to the operating chair, taking the top job at CSA Medical in December 2019 and steering the company through an oversubscribed $53 million Series D and a fully enrolled pivotal trial on the road to FDA approval.

- **Role:** President and CEO at CSA Medical Inc
- **Organizations:** CSA Medical Inc, RejuvenAir, Boston Scientific, MRI Interventions, Wells Fargo Securities / Barrington Associates
- **Nationality:** American
- **Education:** Bachelor of Science in Business Administration (Finance), University of Southern California, Marshall School of Business
- **Known for:** Executed more than $3 billion in medical-device transactions across her business-development career, Led due diligence for Boston Scientific's Advanced Bionics acquisition, entering the implantable microelectronics space, Led negotiations for the CryoCor acquisition, an endocardial cryo-ablation technology for atrial fibrillation

## Career timeline

- **1990s** — Marketing roles at Boston Scientific in the urology and interventional neuroradiology divisions, focused on entering new markets
- **2000-2003** — Investment banker at Barrington Associates (later Wells Fargo Securities), healthcare group
- **2003-2011** — Vice President, Strategy and Business Development at Boston Scientific; led diligence on the Advanced Bionics acquisition and negotiations for CryoCor
- **2011-2014** — Vice President of Emerging Therapies at CSA Medical, developing markets for Spray Cryotherapy including COPD with chronic bronchitis
- **2014-2018** — Vice President of Sales, Marketing and Clinical Operations at MRI Interventions
- **2018** — Returned to CSA Medical as Chief Commercial Officer and President of truFreeze
- **2019** — Appointed President and CEO of CSA Medical in December
- **2024** — Closed an oversubscribed $53 million Series D to fund FDA premarket approval of the RejuvenAir System

## Achievements

- Executed more than $3 billion in medical-device transactions across her business-development career
- Led due diligence for Boston Scientific's Advanced Bionics acquisition, entering the implantable microelectronics space
- Led negotiations for the CryoCor acquisition, an endocardial cryo-ablation technology for atrial fibrillation
- Closed an oversubscribed $53 million Series D for CSA Medical co-led by TVM Capital Life Science and Yonjin Ventures
- Steered the pivotal SPRAY-CB trial to full enrollment ahead of schedule
- Guided the RejuvenAir System to CE Mark clearance in Europe

## Latest updates

- **2024-09** — CSA Medical announced an oversubscribed $53 million Series D financing to support the RejuvenAir System's path to FDA premarket approval.

## Links

- Website: https://rejuvenair.com
- LinkedIn: http://www.linkedin.com/in/wendelin-maners-5636706

---

Profile page: https://yespress.io/wendelin-maners
Published by YesPress — https://yespress.io
Last updated: 2026-07-07